<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651118</url>
  </required_header>
  <id_info>
    <org_study_id>MP4002</org_study_id>
    <nct_id>NCT00651118</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies</brief_title>
  <official_title>Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two allergy medications (azelastine and
      fluticasone) are more effective than placebo or either medication alone (azelastine or
      fluticasone)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, randomized, double-blind, placebo-controlled, parallel-group study
      in subjects with moderate-to-severe seasonal allergic rhinitis (SAR). The study will begin
      with a 7-day, single-blind, placebo lead-in period (Day -7 to Day 1). Subjects will be
      instructed to take placebo lead-in medication twice daily (1 spray per nostril),
      approximately every 12 hours. On Day 1, subjects who satisfy the symptom severity
      requirements and continue to meet all of the study inclusion/exclusion criteria will be
      randomized in a 1:1:1:1 ratio to receive 1 spray per nostril twice daily of MP29-02,
      azelastine hydrochloride, fluticasone propionate, or placebo nasal spray.

      Efficacy will be assessed by the change from baseline in the subject-reported 12-hour
      reflective Total Nasal Symptom Score (TNSS). On Days 1 through 14, subjects will rate the
      instantaneous and reflective TNSS symptoms of sneezing, nasal congestion, runny nose, and
      nasal itching; the instantaneous and reflective total ocular symptom score (TOSS) symptoms of
      itchy eyes, watery eyes and eye redness; and the symptom of postnasal drip, twice daily (AM
      and PM) in a diary prior to the dose of study medication. Symptoms will be scored on a 0 to 3
      scale (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms), such
      that the maximum daily symptom severity score will be 24 for the TNSS and 18 for the TOSS.
      Additional secondary efficacy variables will include reflective individual nasal and ocular
      symptom scores, as well as change from Baseline to Day 14 in the Rhinoconjunctivitis Quality
      of Life Questionnaire (RQLQ).

      Subjects â‰¥ 18 years of age will complete the RQLQ on Day 1 (prior to dosing) and Day 14.
      Subjects will return to the clinic on Day 7 for an interim evaluation. After completing the
      2-week double-blind treatment period, subjects will return to the clinic on Day 14 (or at
      time of early termination) for an end-of-study evaluation. Safety and tolerability
      assessments will be made on Days 7 and 14. Tolerability will be evaluated by subject-reported
      adverse events (AEs), nasal examinations, and vital signs assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>days 1 to 14</time_frame>
    <description>change from baseline in 12-hour reflective(how did you feel in the last 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative value the better the result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative the value the better the result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.
The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement.The more negative the value the better the result.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">832</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastineHcl/fluticasone propionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine Hcl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine Hcl</intervention_name>
    <description>azelastine Hcl 548 mcg</description>
    <arm_group_label>azelastine Hcl</arm_group_label>
    <other_name>azelastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastineHcl / fluticasone propionate</intervention_name>
    <description>azelastine Hcl 548 mcg / fluticasone propionate 200 mcg</description>
    <arm_group_label>azelastineHcl/fluticasone propionate</arm_group_label>
    <other_name>MP29-02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>fluticasone propionate 200 mcg</description>
    <arm_group_label>fluticasone propionate</arm_group_label>
    <other_name>fluticasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 12 years of age and older with a 2 year history of moderate
             to severe seasonal allergic rhinitis

          -  Must be in generally good health

          -  Must meet minimum symptom requirements, as specified in the protocol

          -  Must be wiling and able to provide informed consent and to participate all study
             procedures

          -  Positive skin test to a prevalent spring allergen

        Exclusion criteria:

          -  On nasal examination,the presence of nasal mucosal erosion, nasal ulceration or nasal
             septal perforation

          -  Nasal disease likely to affect the deposition of the medication or evaluation, such as
             sinus infection, nasal polyps or severe deviated septum

          -  Nasal or sinus surgery within the previous 6 months

          -  Chronic sinus infection (more than 3 per year)

          -  Planned travel outside the study area during the study period

          -  Use of any investigational drug within 30 days of the first visit

          -  Hypersensitivity (bad reaction) to azelastine hydrchloride nasal spray (Astelin), or
             fluticasone propionate nasal spray (Flonase)

          -  Women who are not using an acceptable method or birth control

          -  Women who are pregnant or nursing

          -  Upper respiratory tract infection such as common cold, flu, sinus infection within 2
             weeks of first study visit

          -  Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered
             after consultation with the investigator

          -  Irregular heartbeat or other symptomatic heart conditions

          -  History of alcohol or drug abuse

          -  History of glaucoma

          -  Use of medications that could affect the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M. Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy, Asthma and Immunology Associates</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Research Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group and Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Research Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storms Clinical Research Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aeroallergy Research Laboratories of Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy and Asthma</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma and Immunology Associates</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Asthma and Allergy Center</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center</name>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Asthma, Sinus and Allergy Centers</name>
      <address>
        <city>Warren</city>
        <state>New Jersey</state>
        <zip>07059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAIR Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Medical Research</name>
      <address>
        <city>Rockville Center</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Clinic of Tulsa</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma and Dermatology Research</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Consultants of NJ/PA</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Research Associate</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthma and Urticaria of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennesse Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Center of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jane Lee, MD, PA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma, Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <results_first_submitted>May 10, 2012</results_first_submitted>
  <results_first_submitted_qc>August 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2012</results_first_posted>
  <disposition_first_submitted>June 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP29-02</title>
          <description>MP29-02(fluticasone propionate 50 mcg / azelastine HCl 137 mcg) nasal spray</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="P3">
          <title>Azelastine HCl</title>
          <description>azelastine HCl nasal spray nasal spray</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="208"/>
                <participants group_id="P4" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="197"/>
                <participants group_id="P4" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP29-02</title>
          <description>MP29-02(fluticasone propionate 50 mcg / azelastine HCl 137 mcg) nasal spray</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Azelastine HCl</title>
          <description>azelastine HCl nasal spray nasal spray</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="208"/>
            <count group_id="B4" value="210"/>
            <count group_id="B5" value="832"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="166"/>
                    <measurement group_id="B5" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="14.1"/>
                    <measurement group_id="B2" value="38.6" spread="14.1"/>
                    <measurement group_id="B3" value="36.2" spread="14.6"/>
                    <measurement group_id="B4" value="37.3" spread="16.0"/>
                    <measurement group_id="B5" value="37.3" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="133"/>
                    <measurement group_id="B5" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="210"/>
                    <measurement group_id="B5" value="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)</title>
        <description>change from baseline in 12-hour reflective(how did you feel in the last 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative value the better the result.</description>
        <time_frame>days 1 to 14</time_frame>
        <population>intent to treat population (ITT)- must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>MP29-02(fluticasone propionate 50 mcg / azelastine HCl 137 mcg) nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Azelastine HCl</title>
            <description>azelastine HCl nasal spray nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>change from baseline in 12-hour reflective(how did you feel in the last 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative value the better the result.</description>
          <population>intent to treat population (ITT)- must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.2"/>
                    <measurement group_id="O2" value="-4.7" spread="4.7"/>
                    <measurement group_id="O3" value="-4.2" spread="4.6"/>
                    <measurement group_id="O4" value="-2.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
        <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative the value the better the result.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>intent to treat population (ITT)- must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>fluticasone propionate 50 mcg / azelastine HCl 137 mcg nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Azelastine HCl</title>
            <description>azelastine HCl nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)</title>
          <description>change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.
The measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative the value the better the result.</description>
          <population>intent to treat population (ITT)- must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="208"/>
                <count group_id="O4" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="5.3"/>
                    <measurement group_id="O2" value="-4.5" spread="4.7"/>
                    <measurement group_id="O3" value="-4.0" spread="4.7"/>
                    <measurement group_id="O4" value="-2.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</title>
        <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.
The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement.The more negative the value the better the result.</description>
        <time_frame>day 1 to day 14</time_frame>
        <population>intent to treat( ITT)population (18 yrs of age or older) must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP29-02</title>
            <description>MP29-02(fluticasone propionate 50 mcg / azelastine HCl 137 mcg) nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate</title>
            <description>fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Azelastine HCl</title>
            <description>azelastine HCl nasal spray nasal spray</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days</title>
          <description>adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.
The scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement.The more negative the value the better the result.</description>
          <population>intent to treat( ITT)population (18 yrs of age or older) must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="184"/>
                <count group_id="O3" value="174"/>
                <count group_id="O4" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.4"/>
                    <measurement group_id="O2" value="-1.6" spread="1.2"/>
                    <measurement group_id="O3" value="-1.4" spread="1.1"/>
                    <measurement group_id="O4" value="-0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP29-02</title>
          <description>MP29-02(fluticasone propionate 50 mcg / azelastine HCl 137 mcg) nasal spray</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone Propionate</title>
          <description>fluticasone propionate nasal spray</description>
        </group>
        <group group_id="E3">
          <title>Azelastine HCl</title>
          <description>azelastine HCl nasal spray nasal spray</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>placebo nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">dysgusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="208"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators participating in multicenter studies must agree not to present data gathered individually or by a subgroup of centers before the full, initial publication, unless this has been agreed to by all other investigators and Meda Pharmaceuticals.
Meda Pharmaceuticals requests that it receive copies of any intended communication reasonably in advance (at least 15 working days for an abstract or oral presentation and 45 working days for a manuscript)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg,..</name_or_title>
      <organization>Meda Pharmaceutical</organization>
      <phone>732 564 2364</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

